Services of MTRC

MTRC is pleased to announce the release of its latest White Paper: "Transitional Coverage of Innovative Medical Devices in France (pre-LPPR)". This White Paper is designed for medical device manufacturers, market access experts, and health policy leaders who are shaping strategies for early adoption in the French market.

MTRC is pleased to announce the release of its latest White Paper: "Evidence requirements for the creation of IVD reimbursement (NABM) codes in France". This document sheds light on the broader evidence requirements and decision-making framework used by HAS, offering diagnostics manufacturers critical insights into the expectations and potential challenges of securing NABM reimbursement.

Our goal at MTRC is to inform the decision-making of our clients and to support their market access activities. Below is a snapshot of our planned activities for the next two weeks. This can help our existing and prospective clients to understand the potential scope of our support better. From the week of the 19th of May, we plan to work on 17 projects. Review the complete list of planned activities in this post.

MTRC is pleased to introduce a new service to help bridge the gap between clinical research and the evidence expectations of European HTA and reimbursement bodies.

MTRC is pleased to announce the release of its latest White Paper: "Best Reporting Checklists for Studies of Medical Devices". This White Paper explores the best reporting checklists for medical device studies (CONSORT, STROBE, STARD, PRISMA, PRISMA-DTA, SPIRIT, and TIDieR), their key components, and how they improve research transparency.

MTRC is pleased to announce the release of its latest White Paper: "General Market Access Landscape for Health Apps in Europe". This document provides a structured overview of the reimbursement landscape for health apps in three major European countries: England, France, and Germany.

Meet MTRC’s Senior Reimbursement Consultant, Julia Mazur, at the Pharma 4.0 - Digital Healthcare Conference in Berlin. Visit us at Booth #9 to explore tailored solutions in market access, health economics, and evidence synthesis for complex MedTech challenges. Don’t miss Dr. Borisenko’s expert talk on the reimbursement of digital technologies in Europe on 22 May at 10:50 AM.

MTRC is pleased to announce the release of its latest White Paper: "Case study: Market Access Pathway for Preeclampsia Predictive Tests in Germany and Norway". This document provides a detailed case study on how developers of IVD tests can effectively navigate reimbursement pathways in key European markets using the examples of pathways in Germany and Norway.

Our goal at MTRC is to inform the decision-making of our clients and to support their market access activities. Below is a snapshot of our planned activities for the next two weeks. This can help our existing and prospective clients to understand the potential scope of our support better. From the week of the 5th of May, we plan to work on 19 projects. Review the complete list of planned activities in this post.

Our goal at MTRC is to inform the decision-making of our clients and to support their market access activities. Below is a snapshot of our planned activities for the next two weeks. This can help our existing and prospective clients to understand the potential scope of our support better. From the week of the 21st of April, we plan to work on 19 projects. Review the complete list of planned activities in this post.

MTRC is pleased to announce the release of its latest White Paper: "Reimbursement and HTA - Things You Might Be Missing". This document highlights the challenges market access professionals face in staying current with reimbursement and HTA developments and examines how the MTRC Market Access Monitor can help bridge these gaps.

MTRC is pleased to announce the release of its latest White Paper: "Case study: Market Access Pathway for TAVI in France". This document provides a detailed case study on how developers of medical technology (specifically - implants) can successfully navigate reimbursement pathways in key European markets, focusing on France.